BioSenic financials
BioSenic
549300HFIIMTOP1DFR76 | Line item | 2021 | 2020 |
|---|---|---|
| Income statement | ||
| Revenue | €1.0M | €1.0M |
| Other income | €1.7M | €2.7M |
| Operating profit (EBIT) | -€12.0M | -€15.0M |
| Finance costs | €1.1M | €747.0K |
| Profit before tax | -€12.8M | -€15.8M |
| Income tax expense | €89.0K | €78.0K |
| — attributable to owners | -€12.9M | -€11.9M |
| Total comprehensive income | -€12.9M | -€11.9M |
| Cash flow statement | ||
| Cash generated from operations | -€14.6M | -€18.3M |
| Net cash from operating activities | -€12.8M | -€16.1M |
| Net cash from investing activities | -€204.0K | €11.9M |
| Purchase of PP&E (capex) | €193.0K | €78.0K |
| Purchase of intangibles | €14.0K | €15.0K |
| Net cash from financing activities | €7.8M | €10.2M |
| Lease liability payments | €89.0K | €267.0K |
| Balance sheet | ||
| Total assets | €19.8M | €24.8M |
| Non-current assets | €5.5M | €6.0M |
| Property, plant & equipment | €863.0K | €226.0K |
| Current assets | €14.3M | €18.8M |
| Trade & other receivables | €2.6M | €3.8M |
| Cash & equivalents | €9.5M | €14.6M |
| Total equity | -€6.8M | €3.3M |
| — attributable to owners | -€6.8M | €3.3M |
| Non-controlling interests | €0 | €0 |
| Non-current liabilities | €19.9M | €11.7M |
| Current liabilities | €6.7M | €9.8M |
| Derived metrics | ||
| Free cash flow | -€13.0M | -€16.2M |
| Operating margin | -1202.6% | -1501.7% |
| Net margin | -1292.5% | -1194.0% |
| Return on equity | 191.1% | -359.1% |
| Cash conversion ratio | 0.99× | 1.35× |
| Capex coverage | -66.24× | -206.18× |
| Other reported items | ||
| Adjustments For Decrease Increase In Trade and Other Receivables | -€624.0K | -€1.0M |
| Adjustments For Depreciation and Amortisation Expense and Impairment Loss Reversal of Impairment Loss Recognised In Profit Or Loss | €186.0K | €601.0K |
| Adjustments For Increase Decrease In Trade and Other Payables | -€684.0K | €1.7M |
| Adjustments For Sharebased Payments | -€99.0K | €266.0K |
| Basic and Diluted Earnings Loss Per Share From Continuing Operations | €-0.77 | €-1.35 |
| Basic and Diluted Earnings Loss Per Share From Discontinued Operations | €0.00 | €0.33 |
| Cash Advances and Loans From Related Parties | €0 | €1.6M |
| Cash Flows From Losing Control of Subsidiaries Or Other Businesses Classified As Investing Activities | €0 | €12.0M |
| Cash Repayments of Advances and Loans From Related Parties | €675.0K | €1.9M |
| Comprehensive Income Attributable To Owners of Parent | -€12.9M | -€11.9M |
| Current Financial Assets | €1.2M | €0 |
| Current Financial Liabilities | €1.0M | €3.1M |
| Current Tax Liabilities Current | €0 | €0 |
| Equity and Liabilities | €19.8M | €24.8M |
| Finance Income | €333.0K | €0 |
| Gains Losses On Exchange Differences On Translation Recognised In Profit Or Loss | -€20.0K | -€13.0K |
| General and Administrative Expense | €3.1M | €3.3M |
| Income Taxes Paid Refund Classified As Operating Activities | €89.0K | €78.0K |
| Increase Decrease In Cash and Cash Equivalents | -€5.1M | €6.0M |
| Increase Decrease Through Conversion of Convertible Instruments | €0 | €267.0K |
| Increase Decrease Through Sharebased Payment Transactions | -€99.0K | €266.0K |
| Increase Decrease Through Transfer To Statutory Reserve | €0 | €3.0K |
| Increase Decrease Through Transfers and Other Changes Equity | €14.0K | -€48.0K |
| Intangible Assets Other Than Goodwill | €24.0K | €28.0K |
| Interest Paid Classified As Financing Activities | €724.0K | €679.0K |
| Interest Received Classified As Investing Activities | €3.0K | €2.0K |
| Investments In Associates | €12.0K | €12.0K |
| Issue of Equity | €3.3M | €13.5M |
| Issued Capital | €4.9M | €8.4M |
| Liabilities | €26.5M | €21.5M |
| Noncurrent Financial Liabilities | €19.8M | €11.7M |
| Noncurrent Receivables From Taxes Other Than Income Tax | €4.5M | €4.5M |
| Other Adjustments To Reconcile Profit Loss | -€65.0K | -€88.0K |
| Other Current Assets | €1.0M | €328.0K |
| Other Current Liabilities | €804.0K | €1.2M |
| Other Noncurrent Assets | €96.0K | €1.3M |
| Other Noncurrent Liabilities | €112.0K | €0 |
| Other Reserves | €301.0K | €396.0K |
| Payments From Changes In Ownership Interests In Subsidiaries | €0 | €2.0M |
| Proceeds From Issue of Bonds Notes and Debentures | €0 | €4.0M |
| Proceeds From Issuing Shares | €3.3M | €11.8M |
| Profit Loss From Continuing Operations | -€12.9M | -€15.8M |
| Profit Loss From Discontinued Operations | €0 | €3.9M |
| Research and Development Expense | €11.7M | €15.4M |
| Retained Earnings | -€81.5M | -€73.1M |
| Revenue and Operating Income | €2.7M | €3.7M |
| Revenue From Interest | €25.0K | €24.0K |
| Share Issue Related Cost | €277.0K | €966.0K |
| Share of Profit Loss of Associates and Joint Ventures Accounted For Using Equity Method | €0 | €0 |
| Share Premium | €69.5M | €67.6M |
| Trade and Other Current Payables To Trade Suppliers | €4.8M | €5.5M |
Every line item above is a fact tagged in BioSenic's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (EUR), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.